Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.

After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has ...

The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.

As the FDA prepares for a busy Oncologic Drugs Advisory Committee next week, an agency insider told BioSpace that volunteers ...

At a sometimes-contentious U.S. Senate hearing, the Health and Human Services secretary was evasive on the rationale behind ...

Looking for a biopharma job in San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems.

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...